TISIDB

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF16421 E2F transcription factor CC-MB domain PF02319 E2F/DP family winged-helix DNA-binding domain
Function	Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters (PubMed:20176812). Positively regulates transcription of RRP1B (PubMed:20040599).

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000082 G1/S transition of mitotic cell cycle GO:0000083 regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0001101 response to acid chemical GO:0001666 response to hypoxia GO:0001844 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0006839 mitochondrial transport GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0007006 mitochondrial membrane organization GO:0007050 cell cycle arrest GO:0007093 mitotic cell cycle checkpoint GO:0007283 spermatogenesis GO:0007346 regulation of mitotic cell cycle GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008637 apoptotic mitochondrial changes GO:0009410 response to xenobiotic stimulus GO:0010608 posttranscriptional regulation of gene expression GO:0010821 regulation of mitochondrion organization GO:0010822 positive regulation of mitochondrion organization GO:0010948 negative regulation of cell cycle process GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0030900 forebrain development GO:0031570 DNA integrity checkpoint GO:0031571 mitotic G1 DNA damage checkpoint GO:0035794 positive regulation of mitochondrial membrane permeability GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0042770 signal transduction in response to DNA damage GO:0043276 anoikis GO:0043392 negative regulation of DNA binding GO:0043487 regulation of RNA stability GO:0043488 regulation of mRNA stability GO:0043489 RNA stabilization GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044773 mitotic DNA damage checkpoint GO:0044774 mitotic DNA integrity checkpoint GO:0044783 G1 DNA damage checkpoint GO:0044819 mitotic G1/S transition checkpoint GO:0044843 cell cycle G1/S phase transition GO:0045444 fat cell differentiation GO:0045598 regulation of fat cell differentiation GO:0045599 negative regulation of fat cell differentiation GO:0045786 negative regulation of cell cycle GO:0045787 positive regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0046902 regulation of mitochondrial membrane permeability GO:0048144 fibroblast proliferation GO:0048145 regulation of fibroblast proliferation GO:0048146 positive regulation of fibroblast proliferation GO:0048232 male gamete generation GO:0048255 mRNA stabilization GO:0051098 regulation of binding GO:0051100 negative regulation of binding GO:0051101 regulation of DNA binding GO:0051204 protein insertion into mitochondrial membrane GO:0051205 protein insertion into membrane GO:0070341 fat cell proliferation GO:0070344 regulation of fat cell proliferation GO:0070345 negative regulation of fat cell proliferation GO:0070482 response to oxygen levels GO:0070542 response to fatty acid GO:0070585 protein localization to mitochondrion GO:0071156 regulation of cell cycle arrest GO:0071158 positive regulation of cell cycle arrest GO:0071229 cellular response to acid chemical GO:0071396 cellular response to lipid GO:0071398 cellular response to fatty acid GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0071466 cellular response to xenobiotic stimulus GO:0071930 negative regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0072331 signal transduction by p53 class mediator GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072395 signal transduction involved in cell cycle checkpoint GO:0072401 signal transduction involved in DNA integrity checkpoint GO:0072413 signal transduction involved in mitotic cell cycle checkpoint GO:0072422 signal transduction involved in DNA damage checkpoint GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint GO:0072655 establishment of protein localization to mitochondrion GO:0072657 protein localization to membrane GO:0090068 positive regulation of cell cycle process GO:0090150 establishment of protein localization to membrane GO:0090559 regulation of membrane permeability GO:0097193 intrinsic apoptotic signaling pathway GO:0097345 mitochondrial outer membrane permeabilization GO:1900739 regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1901028 regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway GO:1901030 positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902108 regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint GO:1902402 signal transduction involved in mitotic DNA damage checkpoint GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint GO:1902686 mitochondrial outer membrane permeabilization involved in programmed cell death GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1903747 regulation of establishment of protein localization to mitochondrion GO:1903749 positive regulation of establishment of protein localization to mitochondrion GO:1903829 positive regulation of cellular protein localization GO:1904019 epithelial cell apoptotic process GO:1904951 positive regulation of establishment of protein localization GO:1990086 lens fiber cell apoptotic process GO:1990089 response to nerve growth factor GO:1990090 cellular response to nerve growth factor stimulus GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function	GO:0001047 core promoter binding GO:0008134 transcription factor binding
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0005667 transcription factor complex GO:0035189 Rb-E2F complex GO:0044454 nuclear chromosome part GO:0044798 nuclear transcription factor complex GO:0090575 RNA polymerase II transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04110 Cell cycle
Reactome	R-HSA-114452: Activation of BH3-only proteins R-HSA-111448: Activation of NOXA and translocation to mitochondria R-HSA-139915: Activation of PUMA and translocation to mitochondria R-HSA-109581: Apoptosis R-HSA-68867: Assembly of the pre-replicative complex R-HSA-69298: Association of licensing factors with the pre-replicative complex R-HSA-68689: CDC6 association with the ORC R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-69231: Cyclin D associated events in G1 R-HSA-69306: DNA Replication R-HSA-69002: DNA Replication Pre-Initiation R-HSA-113510: E2F mediated regulation of DNA replication R-HSA-1538133: G0 and Early G1 R-HSA-69236: G1 Phase R-HSA-69206: G1/S Transition R-HSA-69205: G1/S-Specific Transcription R-HSA-68911: G2 Phase R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-113501: Inhibition of replication initiation of damaged DNA by RB1/E2F1 R-HSA-109606: Intrinsic Pathway for Apoptosis R-HSA-68874: M/G1 Transition R-HSA-453279: Mitotic G1-G1/S phases R-HSA-453274: Mitotic G2-G2/M phases R-HSA-2559585: Oncogene Induced Senescence R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-1912422: Pre-NOTCH Expression and Processing R-HSA-1912408: Pre-NOTCH Transcription and Translation R-HSA-5357801: Programmed Cell Death R-HSA-69304: Regulation of DNA replication R-HSA-162582: Signal Transduction R-HSA-157118: Signaling by NOTCH R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest R-HSA-3700989: Transcriptional Regulation by TP53

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04110 Cell cycle

Reactome

R-HSA-114452: Activation of BH3-only proteins
R-HSA-111448: Activation of NOXA and translocation to mitochondria
R-HSA-139915: Activation of PUMA and translocation to mitochondria
R-HSA-109581: Apoptosis
R-HSA-68867: Assembly of the pre-replicative complex
R-HSA-69298: Association of licensing factors with the pre-replicative complex
R-HSA-68689: CDC6 association with the ORC
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-69231: Cyclin D associated events in G1
R-HSA-69306: DNA Replication
R-HSA-69002: DNA Replication Pre-Initiation
R-HSA-113510: E2F mediated regulation of DNA replication
R-HSA-1538133: G0 and Early G1
R-HSA-69236: G1 Phase
R-HSA-69206: G1/S Transition
R-HSA-69205: G1/S-Specific Transcription
R-HSA-68911: G2 Phase
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-113501: Inhibition of replication initiation of damaged DNA by RB1/E2F1
R-HSA-109606: Intrinsic Pathway for Apoptosis
R-HSA-68874: M/G1 Transition
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-2559585: Oncogene Induced Senescence
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912408: Pre-NOTCH Transcription and Translation
R-HSA-5357801: Programmed Cell Death
R-HSA-69304: Regulation of DNA replication
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between E2F1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between E2F1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
16052233	Lung Adenocarcinoma	Promote immunity	Importantly, we also provide evidence that E2F1 sensitizes tumor as well as primary cells to apoptosis mediated by FAS ligand or tumor necrosis factor-related apoptosis-inducing ligand, and enhances the cytotoxic effect of T lymphocytes against tumor cells.Overall, our data identify E2F1 as a critical determinant of the cellular response to death-receptor-mediated apoptosis, and suggest that its downregulation contributes to the immune escape of lung adenocarcinoma tumor cells.

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of E2F1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.53	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of E2F1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.554	0.255
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.319	0.859
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.738	0.625
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1.21	0.041
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.214	0.417
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.214	0.558
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.011	0.978
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.284	0.815
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.341	0.791
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.05	0.961
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.24	0.861
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.703	1.27e-05

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of E2F1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of E2F1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of E2F1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by E2F1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of E2F1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of E2F1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between E2F1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	E2F1
Name	E2F transcription factor 1
Aliases	RBBP3; E2F-1; RBAP1; PBR3; PRB-binding protein E2F-1; RBAP-1; RBBP-3; retinoblastoma-associated protein 1; r ......
Chromosomal Location	20q11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting E2F1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse E2F1